This site contains promotional content intended for UK Healthcare Professionals and other relevant decision makers | Not a HCP? Visit our Public Site.
Adverse Event reporting can be found at the bottom of the page | Prescribing Information for the relevant medicine can be found adjacent to the below content and/or in the footer below.
Survival Benefit
In the SHARP study – a pivotal Phase III trial in HCC – Nexavar offered a 31% relative reduction in the risk of death after 1 year
(ARR=11%, Nexavar 44% vs. placebo 33%)
Nexavar increased median OS by 2.8 months vs. placebo.
Adapted from Llovet JM et al. 2008. SHARP was a randomised, double-blind, placebo-controlled, international, multicentre, Phase III study in patients with unresectable HCC (n=602).
Abbreviations: ARR: absolute risk reduction; CI: confidence interval; HCC: hepatocellular carcinoma; HR: hazard ratio; OS: overall survival.
PP-NEX-GB-0225 | March 2025
- Referencesexpand_more
- 1Llovet JM et al. N Engl J Med 2008;359(4):378-390.
- 2Vogel A et al. Ann Oncol 2018;29(4):iv238-iv255.
- 3Personeni N et al. Drugs Context 2018;7:212533.
- 4Finn RS et al. J Hepatol 2018;69(2):353-358.
- 5Bruix J et al. Lancet 2017;389(10064):56-66.
- 6National Institute for Health and Care Excellence (NICE) guidance. Sorafenib for treating advanced hepatocellular carcinoma. Available at: https://www.nice.org.uk/guidance/ta474 (Last Accessed February 2024)
- 7National Institute for Health and Care Excellence (NICE) guidance. Regorafenib for previously treated advanced hepatocellular carcinoma. Available at: https://www.nice.org.uk/guidance/ta555 (Last Accessed February 2024)
- 8Scottish Medicines Consortium. 2018. Advice 1316/18. Available at: https://www.scottishmedicines.org.uk/medicines-advice/regorafenib-stivarga-fullsubmission (Last Accessed February 2024)
- 9Takami T et al. World J Gastroenterol 2016;22(32):7252-7263.
- 10Lencioni R et al. Oncologist 2010;15(4):42-52.
- 11Galle P et al. J Hepatol 2017;67:173-183.